MAG Participates in Blackburn Dubai Property Expo, Highlights Premium Development to British Buyers
12.2.2025 15:51:00 CET | Business Wire | Press release
MAG, one of the UAE’s leading real estate developers, is set to participate in the Blackburn Dubai Property Expo, taking place on 22-23 February at Stanley House Hotel & Spa, UK. The developer will showcase its flagship project, The Ritz-Carlton Residences, Dubai, Creekside, part of the Keturah Resort, presenting a unique opportunity for an unparalleled lifestyle with unmatched service and amenities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212516764/en/
The Ritz-Carlton Residences, Dubai, Creekside at the Keturah Resort (Photo: AETOSWire)
Dubai's real estate sector continues to see strong growth, driven by HNWIs seeking luxury developments. With nearly 740 branded residences globally and that figure expected to double by 2031, Dubai is a key player, with 140 projects in the pipeline. In H1 2024, branded residences made up 7.2% of all property transactions, generating $7.8 billion—12.6% of last year’s total transaction value. These properties offer premium pricing and strong rental yields, making them an attractive investment option.
Located within Keturah Resort, the first fully wellness-certified resort in the MENA region, The Ritz-Carlton Residences, Dubai, Creekside, comprises 200 residences across seven buildings and 12 mansions, each featuring exclusive yacht berthing for residents. Homeowners will benefit from an impressive range of world-class facilities, including a wellness center, a Clubhouse complete with a private members-only club, a ladies’ club, a kids’ club, fine dining and Michelin-star restaurants, a 550-metre promenade, sustainable and organic-focused retail spaces, 24/7 private parking with valet, and a gated community with unique views of the wildlife sanctuary, Burj Khalifa, Dubai Creek Harbor, and Meydan.
David James, Director of Sales at MAG, said: "The UAE’s real estate sector remains strong, with sustained interest from international investors, particularly from the UK. By showcasing Keturah Resort at the Blackburn Dubai Property Expo, we have the opportunity to highlight its unique features and present a premium opportunity set to reshape the real estate landscape in the MENA region."
The project is located on Dubai Creek, providing convenient access to Dubai Downtown, Dubai International Financial Centre, and Dubai International Airport.
For more information, please visit www.theresidencescreeksidedubai.com
Legal Disclaimer
The Ritz-Carlton Residences, Dubai, Creekside, are not owned, developed, or sold by The Ritz-Carlton Hotel Company, LLC or its affiliates (“Ritz-Carlton”). MAG of Life FZ-LLC uses The Ritz-Carlton marks under a license from Ritz-Carlton, which has not confirmed the accuracy of any of the statements or representations made herein.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212516764/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom